8-K: Aquestive Therapeutics Provides Investor Update on Anaphylm and Pipeline Progress

Aquestive Therapeutics is advancing its pipeline, including Anaphylm for anaphylaxis, with a planned NDA submission in early 2025, and is also focused on the commercialization of Libervant for epilepsy.

Summary

• Aquestive Therapeutics is a pharmaceutical company focused on developing innovative medicines using its PharmFilm technology.
• The company's lead product candidate, Anaphylm, is a sublingual epinephrine film for treating anaphylaxis, with a planned NDA submission to the FDA in Q1 2025.
• Anaphylm has completed pivotal studies, meeting all primary and secondary endpoints, and has shown rapid absorption and consistent pharmacokinetics.
• The company is also developing AQST-108, a topical epinephrine gel, using its Adrenaverse prodrug platform.
• Libervant, a buccal film for epilepsy, is currently approved for patients aged 2 to 5 years, with plans to launch for older age groups pending regulatory approvals.
• Aquestive anticipates total revenues of approximately $57 to $60 million in 2024 and a non-GAAP adjusted EBITDA loss of approximately $20 to $23 million.
• The company has extended its cash runway into 2026 following a $77.5 million public offering.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the company's pipeline and clinical progress, particularly for Anaphylm. However, it also acknowledges the financial challenges and risks associated with drug development and commercialization. The sentiment is generally optimistic but tempered by the realities of the pharmaceutical industry.

Positives

• Anaphylm has demonstrated positive clinical results, meeting all primary and secondary endpoints in pivotal studies.
• Anaphylm has a consistent pharmacokinetic profile and rapid absorption, with a Tmax of 12-15 minutes.
• The company has a clear path to NDA submission for Anaphylm by Q1 2025.
• Aquestive has a diversified pipeline with multiple product candidates in development.
• The company has a strong intellectual property portfolio with over 150 patents worldwide.
• Aquestive has a dedicated and experienced leadership team.
• The company has a strong manufacturing capability with over 2 billion PharmFilm doses distributed worldwide.

Negatives

• Aquestive is currently operating at a loss, with an expected non-GAAP adjusted EBITDA loss of $20 to $23 million in 2024.
• The company faces competition from existing epinephrine products and potential generics.
• There is a risk of delays in the regulatory approval process for Anaphylm and other product candidates.
• Aquestive needs to overcome the orphan drug market exclusivity for Libervant for patients aged 6 and older, which extends to January 2027.
• The company is reliant on the success of its pipeline products to drive future revenue growth.
• There is a risk of eroding market share for Suboxone, which currently accounts for a substantial part of the company's revenue.

Risks

• There are risks associated with the development and clinical trials of Anaphylm, AQST-108, and other product candidates, including potential delays or changes in timing and cost.
• The company faces the risk of not receiving FDA approval for its product candidates, including Anaphylm and AQST-108.
• There is a risk that Aquestive may not be able to overcome the orphan drug market exclusivity for Libervant for patients aged 6 and older.
• The company faces risks related to commercializing new products, including technology, financial, market, and regulatory risks.
• There is a risk of insufficient capital and cash resources to fund commercialization and future clinical development activities.
• Aquestive faces risks related to manufacturing capabilities, intellectual property rights, and potential litigation.
• The company is exposed to risks related to general economic, political, and market conditions, including the impact of the COVID-19 pandemic.

Future Outlook

Aquestive plans to submit an NDA for Anaphylm in Q1 2025 and launch Libervant for patients aged 6 to 11 years, pending FDA approval. The company anticipates continued growth in the epinephrine market and expects to leverage its commercial infrastructure for future product launches.

Management Comments

• Management is focused on advancing medicines to bring meaningful improvement to patients' lives.
• The company is committed to leveraging its PharmFilm technology to develop innovative products.
• Management believes Anaphylm has the potential to be a significant advancement in the treatment of anaphylaxis.
• The company is confident in its ability to commercialize Libervant and other product candidates.

Industry Context

Aquestive is operating in the pharmaceutical industry, specifically focusing on drug delivery technologies. The company is targeting the epinephrine market, which is currently dominated by auto-injectors. The development of Anaphylm, an oral epinephrine film, represents a potential disruption in this market. The company is also addressing the epilepsy market with Libervant, competing with existing treatments.

Comparison to Industry Standards

• Aquestive's Anaphylm is being developed as a novel oral alternative to epinephrine auto-injectors, which are the current standard of care for anaphylaxis. Competitors include Mylan's EpiPen and Kaleo's Auvi-Q.
• The company's clinical trial results for Anaphylm show comparable pharmacokinetic profiles to these injectable products, with a faster Tmax than EpiPen and Auvi-Q.
• Aquestive's PharmFilm technology is a differentiator, as it allows for oral thin film delivery, which is not a common method for epinephrine administration.
• The company's Libervant product competes with other diazepam products for epilepsy, including nasal sprays, but offers a buccal film formulation.
• Aquestive's manufacturing capabilities, with over 2 billion doses of oral thin film distributed, position it as a leader in this technology.

Stakeholder Impact

• Shareholders may benefit from the potential success of Anaphylm and other pipeline products.
• Patients may benefit from new treatment options for anaphylaxis and epilepsy.
• Employees may benefit from the company's growth and success.
• Customers may benefit from access to innovative drug delivery technologies.

Next Steps

• Aquestive plans to submit an NDA for Anaphylm in Q1 2025.
• The company will continue to advance the clinical development of AQST-108.
• Aquestive will launch Libervant for patients aged 6 to 11 years, pending FDA approval.
• The company will focus on driving awareness and adoption of its products among healthcare providers.

Key Dates

Keywords

Anaphylm, epinephrine, PharmFilm, anaphylaxis, Libervant, AQST-108, oral thin film, FDA, clinical trials, regulatory approval, drug delivery, pharmaceuticals